Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

193.59B

Market cap193.59B

Price-Earnings ratio

10.07

Price-Earnings ratio10.07

Dividend yield

2.86%

Dividend yield2.86%

Average volume

12.59M

Average volume12.59M

High today

$44.37

High today$44.37

Low today

$42.71

Low today$42.71

Open price

$44.05

Open price$44.05

Volume

10.86M

Volume10.86M

52 Week high

$81.44

52 Week high$81.44

52 Week low

$35.12

52 Week low$35.12

NVO News

Nasdaq 4h

Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?

Key Points Wall Street likes stories, and a big one today is the huge demand for GLP-1 weight-loss drugs. Novo Nordisk got off to an early lead, but Eli Lilly...

Simply Wall St 11h

Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle

Novo Nordisk (NYSE:NVO) has entered a clinical supply agreement with Veru Inc. to provide Wegovy for a pivotal Phase 2b obesity trial in older adults. The agre...

TipRanks 2d

Veru announces clinical supply agreement with Novo Nordisk

In a regulatory filing, Veru (VERU) announced that on June 2, the company entered into a clinical supply agreement with Novo Nordisk A/S (NVO) in conjunction wi...

Analyst ratings

54%

of 37 ratings

Buy

37.8%

Hold

54.1%

Sell

8.1%

More NVO News

TipRanks 2d

Novo Nordisk Expands Obesity and Diabetes Pipeline With New Phase 1 Trial of NNC0497-0040

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings...

Bloomberg 2d

Denmark to Study Whether Wegovy Can Get More People Working

The new government in Novo Nordisk A/S ’s home country of Denmark wants to test whether weight-loss drugs can help get more people into work, adding a new econo...

TipRanks 3d

Major Insider Makes Bold Move in Prothena Stock

New insider activity at Prothena ( (PRTA) ) has taken place on June 3, 2026. Claim 55% Off TipRanks Unlock trusted, data-backed investing tools with TipRanks Pr...

Nasdaq 3d

Here's What I Think Is Really Going on With Novo Nordisk Stock

Key Points Novo Nordisk lost momentum in the GLP-1 market. The company's deep pipeline could allow it to bounce back. 10 stocks we like better than Novo Nord...

Reuters 3d

Novo Nordisk launches Wegovy in UAE - Reuters

...

The Wall Street Journal 3d

Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE

The Emirates Drug Establishment said this week that it had approved Novo Nordisk's once-daily tablet. Novo Nordisk Novo Nordisk NOVO.B -2.54 %decrease; red dow...

Nasdaq 4d

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down

Key Points VK2735 is being developed in both subcutaneous and oral forms, and upcoming Phase 1 maintenance trial results are a major catalyst. VK2735 may offe...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.